GeneSwissMeds prescribe Switzerland.
Type 2 Diabetes Mellitus (T2DM) in remission effortlessly. Physicians Formulated.
V-Trosegenes V1™V2™Backed by 25 years of Clinical Studies. Trusted by Top 5 Swiss Private Hospitals. Access to Switzerland Premium Private Clinics BioTechnology Breakthrough Treatment
A wealth of in vitro and in vivo evidence has already demonstrated that specific extracts of neoflavonoid-rich plants could be a promising therapeutic agent in preventing type 2 diabetes mellitus (T2DM). Neoflavonoid intake has had significant positive results in regulating glucose metabolism and stabilizing blood glucose values.
Over 25 years of clinical trials, we have examined the effect of combined daily dosages of V1™ (V-Trosegenes 1) and V2™ (V-Trosegenes 2) in supporting the regulation of glucose metabolism and stabilizing blood glucose values. V1™ and V2™ contain proprietary extracts of Wild Grown Hintonia latiflora, Organic Grifola frondosa, Organic Coprinus comatus, Organic Cordyceps militaris, Organic Ophiocordyceps sinensis, and Salacia oblonga. These extracts contain the highest grade of polyphenols, polysaccharides, and carotenoids.
Our trials have included five groups of 3,000 patients, comprising 1,500 females and 1,500 males with an average age of 67 and a median age of 54. All patients consume either Alpha-glucosidase inhibitors, SGLT 2 inhibitors, DPP 4 inhibitors, Sitagliptin, Biguanides, meglitinides, sulfonylureas, or thiazolidinediones, either alone or in combination.
Each of the five groups of patients has been closely monitored for T2DM biomarkers throughout each trial, including fasting blood glucose and hemoglobin A1c.
In all five groups, patients have shown significant improvements in blood glucose control parameters. The total reduction of fasting blood glucose over all five groups has ranged from 7.3% to 43.3%, with an average decrease of 40% in A1C levels within one month. This effect has been maintained for the duration of each trial. Several other biomarkers have also been positively regulated, and patients’ liver and lipid values were positively affected. The V1™ and V2™ dosage regimes have been well-tolerated, with no adverse effects reported.
Our patent-pending extract Biotechnology scientific research clinically showed an average of 300% higher absorption rate in the bloodstream, translating to immediate results as fast as one week.
Our studies confirm the positive effect of V1™ and V2™ in managing glucose metabolism and preventing T2DM. These results are consistent with earlier studies using extracts of Hintonia latiflora and indicate the significant therapeutic potential of V1 and V2 in the overall management and prevention of T2DM.
More information can be found at https://www.geneswissmeds.com/
About GeneSwissMeds
Our dedicated Switzerland based team comprises distinguished and respected experts, including medical doctors, medical researchers, and scientists.
Media Contact
Company Name: GeneSwissMeds
Contact Person: Ms. Gail March
Email: Send Email
Country: United States
Website: https://geneswissmeds.com/v/
